Avid Bioservices, a CDMO focused on biopharmaceutical products derived from mammalian cell culture, has advanced the ongoing expansion of its process development capabilities and labs, initiating demolition work at the site that will ultimately provide an additional 3,000 sq.-ft. of space.

The newly constructed lab will allow for the consolidation of cell line development, upstream process development and upstream pilot scale production in a single location with the latest equipment.  Once complete, this facility will be used for on-boarding new clients for the delivery of robust, compliant, viable biologics manufacturing processes and executing technology transfer of existing processes. Avid’s cell culture development also includes a range of purification and analytical development services.
 
Some additional plans for the lab include: bioreactor development and control systems, a higher level of automation and reporting capabilities, the tripling of the current capacity provided by benchtop bioreactor systems, as well as the hiring of additional process development scientists.